Breaking News Instant updates and real-time market news.

RUBY

Rubius Therapeutics

$16.29

-1.15 (-6.59%)

, BLUE

Bluebird Bio

$146.64

-9.56 (-6.12%)

08:13
03/25/19
03/25
08:13
03/25/19
08:13

Rubius Therapeutics appoints Greg Whitehead CQO

Rubius Therapeutics (RUBY) announced the appointment of Greg Whitehead as senior VP and CQO. Whitehead brings more than 25 years of quality related experience to Rubius. He joins the company from Bluebird Bio (BLUE) where he most recently served as VP, quality.

RUBY

Rubius Therapeutics

$16.29

-1.15 (-6.59%)

BLUE

Bluebird Bio

$146.64

-9.56 (-6.12%)

  • 08

    Apr

RUBY Rubius Therapeutics
$16.29

-1.15 (-6.59%)

08/13/18
LEER
08/13/18
INITIATION
Target $30
LEER
Outperform
Rubius Therapeutics initiated with an Outperform at Leerink
Leerink analyst Jonathan Chang started Rubius Therapeutics with an Outperform rating and $30 price target as he has a positive long-term view on the stock. While the analyst acknowledges that any valuation method has significant shortcomings at this early stage, he believes that Rubius is "a swing for the fences type of play" with an approach that is uniquely differentiated and could be potentially transformative for the cell therapy field, if successful. Additionally, he views it as well positioned to execute on its strategy with a highly experienced management team and strong financial position.
08/13/18
JEFF
08/13/18
INITIATION
Target $40
JEFF
Buy
Jefferies starts Rubius Therapeutics with Buy rating, $40 target
Jefferies analyst Michael Yee initiated coverage of Rubius Therapeutics with a Buy rating and $40 price target. The company's platform technology could broadly address a number of blockbuster markets, Yee tells investors in a research note. He sees an "asymmetric risk/reward over time" for the shares.
08/13/18
08/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Crinetics (CRNX) was initiated with an Outperform at Leerink, an Overweight at Piper Jaffray, and a Neutral at JPMorgan. 2. Hasbro (HAS) was initiated with an Overweight at Consumer Edge while Mattel (MAT) initiated with an Equal Weight. 3. Allakos (ALLK) initiated with an Outperform at William Blair, a Buy at Jefferies, and a Neutral at Goldman Sachs. 4. Constellation Pharmaceuticals (CNST) was initiated with an Overweight at JPMorgan as well as an Outperform at BMO Capital and Oppenheimer. 5. Rubius Therapeutics (RUBY) initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/18
08/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN SACHS CUTS ALNYLAM TO BUY: Goldman Sachs analyst Terence Flynn downgraded Alnylam (ALNY) to Buy from Conviction Buy. The analyst also lowered his price target for the shares to $155 from $193. Flynn said the lack of cardio data in the approved U.S. label for Onpattro is disappointing and could represent a disadvantage versus Pfizer's (PFE) competitor drug Tafamadis. Piper Jaffray analyst Edward Tenthoff recommended buying shares of Alnylam Pharmaceuticals on weakness following the approval of Onpattro. Morgan Stanley analyst David Lebowitz lowered his price target to $93, Nomura Instinet analyst Christopher Marai lowered his price target to $73, and Stifel analyst Paul Matteis maintained a Buy rating but cut his price target to $123 from $125 and slightly lowered his revenue ramp for the drug based on modestly reduced share in mixed-phenotype haTTR patients and lower share in cardiac-only haTTR patients. B. Riley FBR analyst Madhu Kumar raised his price target to $230. RUBIUS THERAPEUTICS INITIATED AT MULTIPLE FIRMS: Rubius Therapeutics (RUBY) was initiated with an Outperform at Leerink, an Overweight at JPMorgan and Morgan Stanley, as well as a Buy at Jefferies. PIPER JAFFRAY SAYS AMAZON AD BUSINESS GROWING INTO PROFIT DRIVER: Amazon's (AMZN) advertising business "has been quietly growing into a massive driver of current and future profitability," Piper Jaffray analyst Michael Olson told investors in a research note. Applying an advertising comp multiple of 16 times to estimated 2020 Amazon advertising operating income suggests an ad business that should be valued at $150B-$190B, Olson contended. IMPERIAL CAPITAL CUTS NETFLIX PRICE TARGET TO $494: Imperial Capital analyst David Miller lowered his price target for Netflix (NFLX) to $494 after he slightly reduced his global subscriber estimates. The analyst said that in the "interest of being conservative," he decreased his fiscal 2018 global subscriber estimate to 141.2M from 141.4M and fiscal 2019 global subscriber estimate to 164.4M from 166.3M. DISH DOWNGRADED TO SELL AT MOFFETTNATHANSON: MoffettNathanson analyst Craig Moffett downgraded Dish (DISH) to Sell from Neutral with a price target of $29 and noted that while the reported Q2 business conditions in the core satellite TV business were "genuinely better" amid reduced churn and slower subscriber losses, the Spectrum segment -- which holds "all" of the company's equity value -- is worse.
BLUE Bluebird Bio
$146.64

-9.56 (-6.12%)

02/25/19
RHCO
02/25/19
NO CHANGE
Target $184
RHCO
Buy
Bluebird Bio price target lowered to $184 from $223 at SunTrust
SunTrust analyst Edward Nash lowered his price target on Bluebird Bio to $184 to reflect his updated expectations of E.U. LentiGlobin approval and bookings coming in 2020, rather 2019, along with a shallower penetration curve of the treatment in the U.S. The analyst is also keeping his Buy rating on the shares and sees Bluebird Bio as "best positioned to transition gene therapy from a scientific endeavor to a successful commercial proposition" given its "five potentially curative products in the clinic".
02/25/19
COWN
02/25/19
INITIATION
COWN
Outperform
Bluebird Bio coverage transferred with an Outperform at Cowen
Cowen analyst Yaron Werber assumed coverage on Bluebird Bio with an Outperform. The analyst believes that investors should have a strong interest in the stock, as bluebird has a deep pipeline, and is launching three drugs in 2019-2020, with "a slew of data" coming in 2019.
03/05/19
LEER
03/05/19
DOWNGRADE
LEER
Market Perform
Bluebird Bio downgraded to Market Perform from Outperform at SVB Leerink
03/05/19
03/05/19
DOWNGRADE
Target $145

Market Perform
Bluebird Bio downgraded to Market Perform on valuation at SVB Leerink
As previously reported, SVB Leerink analyst Mani Foroohar downgraded Bluebird Bio to Market Perform from Outperform, with a $145 price target. While the analyst remains optimistic on the company's ability to secure approval for BCMA, Lenti-D, and LentiGlobin programs, he believes the current valuation reflects these attractive fundamentals in line with his high probability of success assumptions.

TODAY'S FREE FLY STORIES

PBYI

Puma Biotechnology

$8.71

0.24 (2.83%)

18:08
12/11/19
12/11
18:08
12/11/19
18:08
Hot Stocks
Puma Biotechnology presents Phase II results of neratinib in breast cancer »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$23.06

-0.18 (-0.77%)

18:05
12/11/19
12/11
18:05
12/11/19
18:05
Hot Stocks
G1 Therapeutics presents data from Phase 1b/2a trial of lerociclib at SABCS »

G1 Therapeutics reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NH

NantHealth

$0.86

-0.0225 (-2.54%)

18:01
12/11/19
12/11
18:01
12/11/19
18:01
Hot Stocks
NantHealth presents new breast cancer research findings at SABCS »

NantHealth announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$30.56

0.71 (2.38%)

, AAPL

Apple

$270.71

2.09 (0.78%)

17:51
12/11/19
12/11
17:51
12/11/19
17:51
Hot Stocks
Twitter announces support for iOS Live Photos that will show as GIFs »

Earlier today Twitter…

TWTR

Twitter

$30.56

0.71 (2.38%)

AAPL

Apple

$270.71

2.09 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

GVA

Granite Construction

$26.29

0.97 (3.83%)

17:46
12/11/19
12/11
17:46
12/11/19
17:46
Hot Stocks
Granite Construction awarded $14M site development project in Illinois »

Granite's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRL

Brigham Minerals

$18.60

0.4 (2.20%)

17:45
12/11/19
12/11
17:45
12/11/19
17:45
Syndicate
Brigham Minerals 11M share Secondary priced at $18.10 »

Credit Suisse, Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KHC

Kraft Heinz

$31.59

-0.29 (-0.91%)

17:39
12/11/19
12/11
17:39
12/11/19
17:39
Initiation
Kraft Heinz initiated  »

Kraft Heinz resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.17

-0.48 (-0.72%)

17:37
12/11/19
12/11
17:37
12/11/19
17:37
Initiation
Kellogg initiated  »

Kellogg resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.32

-0.085 (-0.59%)

17:34
12/11/19
12/11
17:34
12/11/19
17:34
Hot Stocks
UAW ratifies CBA with Fiat Chrysler »

UAW Fiat Chrysler U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

FLO

Flowers Foods

$21.54

-0.04 (-0.19%)

17:27
12/11/19
12/11
17:27
12/11/19
17:27
Initiation
Flowers Foods initiated  »

Flowers Foods resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:25
12/11/19
12/11
17:25
12/11/19
17:25
General news
U.S. Treasury posted a -$208.8 B budget deficit in November »

U.S. Treasury posted a…

NOMD

Nomad Foods

$20.54

-0.12 (-0.58%)

17:23
12/11/19
12/11
17:23
12/11/19
17:23
Initiation
Nomad Foods initiated  »

Nomad Foods resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMPX

LMP Automotive

$15.05

1.75 (13.16%)

17:23
12/11/19
12/11
17:23
12/11/19
17:23
Hot Stocks
LMP Automotive Chairman Samer Tawfik buys over $1.7M in company shares »

LMP Automotive Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$28.91

0.1 (0.35%)

17:21
12/11/19
12/11
17:21
12/11/19
17:21
Syndicate
Breaking Syndicate news story on Triumph Group »

Triumph Group files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$170.70

-0.635 (-0.37%)

17:12
12/11/19
12/11
17:12
12/11/19
17:12
Initiation
McCormick initiated  »

McCormick resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$33.37

0.27 (0.82%)

17:10
12/11/19
12/11
17:10
12/11/19
17:10
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$51.57

-1.67 (-3.14%)

, K

Kellogg

$66.17

-0.48 (-0.72%)

17:08
12/11/19
12/11
17:08
12/11/19
17:08
Initiation
General Mills, Kellogg initiated  »

General Mills resumed…

GIS

General Mills

$51.57

-1.67 (-3.14%)

K

Kellogg

$66.17

-0.48 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CEI

Camber Energy

$2.05

0.86 (72.27%)

17:05
12/11/19
12/11
17:05
12/11/19
17:05
Hot Stocks
Camber Energy responds to unusual market activity »

Camber Energy commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$0.69

0.0554 (8.73%)

17:04
12/11/19
12/11
17:04
12/11/19
17:04
Conference/Events
Miragen Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGI

Alamos Gold

$5.57

0.205 (3.82%)

17:03
12/11/19
12/11
17:03
12/11/19
17:03
Hot Stocks
Alamos Gold sees FY20 production 425K-465K ounces of gold »

Alamos Gold provided 2020…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Earnings
MedMen sees positive adjusted EBITDA in Q121, and positive FCF in Q321 »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CPB

Campbell Soup

$48.00

-0.37 (-0.76%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Initiation
Campbell Soup initiated  »

Campbell Soup resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:00
12/11/19
12/11
17:00
12/11/19
17:00
Earnings
MedMen sees FY20 revenue $225M - $245M, consensus $212.69M »

Sees FY21 revenue $450 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

XOM

Exxon Mobil

$68.95

-0.11 (-0.16%)

16:59
12/11/19
12/11
16:59
12/11/19
16:59
Hot Stocks
Exxon Mobil's Milton sells 13,569 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SJM

J.M. Smucker

$104.42

-1.64 (-1.55%)

16:57
12/11/19
12/11
16:57
12/11/19
16:57
Initiation
J.M. Smucker initiated  »

J.M. Smucker resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.